Chronic rhinosinusitis with nasal polyps (CRSwNP) is a debilitating chronic inflammatory disease of the nasal and paranasal sinuses of the upper airways, affecting up to 8.9 million patients in Europe. Despite the significant daily impact on the health and well-being of patients, across countries there has been minimal policymaker recognition of CRSwNP and its impact.
The objective of this report, commissioned by the BeyondTheNose initiative organised and funded by GSK, was to assess the barriers in the policy environment affecting provision of care for those with CRSwNP. In addition to detailing the evidence on the impact of the disease and the challenges facing patients, CRA worked with a group of patient and physician experts drawn from the BeyondTheNose Alliance to develop recommendations for policy changes that could deliver improvements in the care and management of the disease.
Based on the review of the literature, evidence of the burden of the disease, case studies from similar therapy areas, and discussions with the expert working group, this report sets out recommendations for policymakers in four areas:
- Addressing the lack of policymaker recognition and broader disease awareness;
- Accelerating the speed of diagnosis and referral;
- Optimising and modernising care pathways; and
- Promoting access to the treatments that best serve patients.
The findings and recommendations in this report have been endorsed by: the European Forum for Research and Education in Allergy and Airway Diseases (EUFOREA); the Spanish Association for Patients with Nasal Polyps (AEPONA); the Association Asthme & Allergies (French Asthma & Allergies Association); and Respiriamo Insieme – APS. The authors would also like to thank the European Academy of Allergy & Clinical Immunology (EAACI) for their insights in developing the findings and recommendations in this report.
NP-GBL-RS-WCNT-260001 | DOP March 2026
